Solventum Corporation $SOLV Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its stake in Solventum Corporation (NYSE:SOLV) by 13.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,053 shares of the company’s stock after selling 7,438 shares during the period. Russell Investments Group Ltd.’s holdings in Solventum were worth $3,491,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC acquired a new stake in Solventum in the first quarter valued at $216,000. Bessemer Group Inc. increased its stake in Solventum by 17.1% during the first quarter. Bessemer Group Inc. now owns 1,963 shares of the company’s stock valued at $150,000 after purchasing an additional 287 shares during the last quarter. Perigon Wealth Management LLC raised its holdings in shares of Solventum by 3.8% during the first quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company’s stock worth $331,000 after purchasing an additional 159 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Solventum by 140.6% during the first quarter. Farther Finance Advisors LLC now owns 1,821 shares of the company’s stock worth $139,000 after purchasing an additional 1,064 shares during the period. Finally, Amalgamated Bank raised its holdings in shares of Solventum by 1.3% during the first quarter. Amalgamated Bank now owns 27,120 shares of the company’s stock worth $2,062,000 after purchasing an additional 352 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SOLV shares. Wells Fargo & Company increased their target price on shares of Solventum from $75.00 to $79.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. KeyCorp initiated coverage on shares of Solventum in a research report on Friday, June 6th. They issued a “sector weight” rating for the company. Wall Street Zen lowered shares of Solventum from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Argus raised shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target for the company in a report on Tuesday, July 1st. Finally, Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $80.00 to $103.00 in a report on Tuesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Solventum has an average rating of “Hold” and a consensus price target of $85.75.

Solventum Trading Up 2.0%

Shares of SOLV stock opened at $73.46 on Friday. Solventum Corporation has a 12 month low of $59.35 and a 12 month high of $85.92. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. The business’s 50 day moving average is $73.79 and its two-hundred day moving average is $72.86. The company has a market cap of $12.74 billion, a PE ratio of 34.01, a price-to-earnings-growth ratio of 1.78 and a beta of 0.52.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The company had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same quarter last year, the company posted $1.56 earnings per share. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.